Immutep Ltd ADR (IMMP)

$2.88 +0.09 (3.23%)
Market Cap 411.17M
Revenue (ttm) 6.69M
Net Income (ttm) -39.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -594.62%
Debt to Equity Ratio 0.01
Volume 344,300
Avg Vol 268,990
Day's Range N/A - N/A
Shares Out 147.37M
Stochastic %K 74%
Beta 1.76
Analysts Strong Sell
Price Target $8.33

Company Profile

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 2 8315 7003
Fax: 61 2 8569 1880
Address:
Australia Square, Level 32 264 George Street, Sydney, Australia
NOCKNOCK
NOCKNOCK Feb. 24 at 3:34 PM
$IMMP
0 · Reply
TheIrishCzar
TheIrishCzar Feb. 24 at 1:55 PM
$IMMP options market is expecting a big move one way or the other by March expiration
0 · Reply
Pupssavethe
Pupssavethe Feb. 24 at 1:22 PM
$IMMP brewing big time and it is not my coffee
0 · Reply
TheIrishCzar
TheIrishCzar Feb. 24 at 12:05 AM
$IMMP citizen’s upped its price target to $10, just 6 days after setting a 6$ target. Hmmm? https://www.gurufocus.com/news/8642747/immutep-immp-receives-updated-analyst-coverage-with-new-price-target-immp-stock-news
0 · Reply
bylocehi
bylocehi Feb. 23 at 7:46 PM
$IMMP suspect buyers are short sellers closing positions on a down day.
0 · Reply
NOCKNOCK
NOCKNOCK Feb. 23 at 2:58 PM
$IMMP
0 · Reply
IFeelLike
IFeelLike Feb. 22 at 6:28 PM
$IMMP want to emphasize this again.... Concerning Tacti-004: NEW STANDARD OF CARE!! More numbers: market size expected to be 48 billion USD!!
3 · Reply
IFeelLike
IFeelLike Feb. 22 at 6:18 PM
$IMMP numbers don't lie.... Immutep the only one to address all Lung cancer populations as mentioned here👌💪
0 · Reply
allsign
allsign Feb. 21 at 8:38 AM
$IMMP https://www.immutep.com/dw/uploads/2026/02/Immutep_Corporate_Presentation_Feb2026.pdf
1 · Reply
NOCKNOCK
NOCKNOCK Feb. 21 at 12:14 AM
$IMMP
0 · Reply
Latest News on IMMP
Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

Fri, 06 Feb 2026 08:00:00 -0500 - 18 days ago

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

Immutep Quarterly Activities Report Q2 FY26

Thu, 29 Jan 2026 08:00:00 -0500 - 26 days ago

Immutep Quarterly Activities Report Q2 FY26

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

Mon, 22 Dec 2025 08:00:00 -0500 - 2 months ago

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug

Mon, 08 Dec 2025 02:34:15 -0500 - 2 months ago

India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug

Dr. Reddy’s Laboratories enters strategic collaboration with Immutep SAS for exclusive licensing of eftilagimod alfa

2025-12-08T07:28:15.000Z - 2 months ago

Dr. Reddy’s Laboratories enters strategic collaboration with Immutep SAS for exclusive licensing of eftilagimod alfa

Immutep Limited (IMMP) Presents at ESMO Congress 2025 - Slideshow

2025-10-20T23:02:57.000Z - 4 months ago

Immutep Limited (IMMP) Presents at ESMO Congress 2025 - Slideshow

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

Mon, 20 Oct 2025 08:01:00 -0400 - 4 months ago

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Mon, 08 Sep 2025 08:00:00 -0400 - 6 months ago

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Immutep Quarterly Activities Report Q4 FY25

Wed, 30 Jul 2025 08:00:00 -0400 - 7 months ago

Immutep Quarterly Activities Report Q4 FY25

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Tue, 29 Jul 2025 08:00:00 -0400 - 7 months ago

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

Tue, 27 May 2025 08:00:00 -0400 - 9 months ago

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

Thu, 15 May 2025 15:50:04 -0400 - 10 months ago

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

Immutep Limited: Surging On Positive Head And Neck Data

2025-05-08T12:46:59.000Z - 10 months ago

Immutep Limited: Surging On Positive Head And Neck Data

Immutep to Participate in Upcoming Investor Conferences

Wed, 02 Apr 2025 08:00:00 -0400 - 11 months ago

Immutep to Participate in Upcoming Investor Conferences

Immutep Quarterly Activities Report Q2 FY25

Fri, 31 Jan 2025 08:00:00 -0500 - 1 year ago

Immutep Quarterly Activities Report Q2 FY25

Immutep Limited: Continuing To Make The Case For Eftilagimod

2025-01-28T21:37:29.000Z - 1 year ago

Immutep Limited: Continuing To Make The Case For Eftilagimod

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Tue, 17 Dec 2024 08:00:00 -0500 - 1 year ago

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Thu, 12 Dec 2024 08:15:00 -0500 - 1 year ago

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Fri, 15 Nov 2024 15:18:16 -0500 - 1 year ago

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Thu, 14 Nov 2024 11:16:11 -0500 - 1 year ago

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Thu, 14 Nov 2024 08:15:00 -0500 - 1 year ago

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Immutep Quarterly Activities Report Q1 FY25

Tue, 29 Oct 2024 08:00:00 -0400 - 1 year ago

Immutep Quarterly Activities Report Q1 FY25

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Thu, 10 Oct 2024 08:00:00 -0400 - 1 year ago

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Immutep: Navigating The Bumps In The Road

Mon, 07 Oct 2024 09:10:11 -0400 - 1 year ago

Immutep: Navigating The Bumps In The Road

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Mon, 16 Sep 2024 08:00:00 -0400 - 1 year ago

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Immutep Ltd Clinical Results Webinar Transcript

2024-09-14T11:19:07.000Z - 1 year ago

Immutep Ltd Clinical Results Webinar Transcript

Immutep Ltd Webcast Presentation Transcript

2024-09-14T11:19:05.000Z - 1 year ago

Immutep Ltd Webcast Presentation Transcript

Immutep Quarterly Activities Report Q4 FY24

Wed, 31 Jul 2024 08:00:00 -0400 - 1 year ago

Immutep Quarterly Activities Report Q4 FY24

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Mon, 15 Jul 2024 13:54:02 -0400 - 1 year ago

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Thu, 11 Jul 2024 18:40:00 -0400 - 1 year ago

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Wed, 03 Jul 2024 08:00:00 -0400 - 1 year ago

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Tue, 25 Jun 2024 08:00:00 -0400 - 1 year ago

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Immutep successfully completes institutional placement and institutional component of entitlement offer

Wed, 05 Jun 2024 06:00:00 -0400 - 1 year ago

Immutep successfully completes institutional placement and institutional component of entitlement offer

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Sun, 02 Jun 2024 20:38:00 -0400 - 1 year ago

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

Wed, 15 May 2024 08:00:00 -0400 - 1 year ago

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Thu, 02 May 2024 08:00:00 -0400 - 1 year ago

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Immutep: Realizing The Expected Catalysts, With More To Come

Wed, 01 May 2024 12:39:01 -0400 - 1 year ago

Immutep: Realizing The Expected Catalysts, With More To Come

Immutep Quarterly Activities Report Q3 FY24

Mon, 29 Apr 2024 08:00:00 -0400 - 1 year ago

Immutep Quarterly Activities Report Q3 FY24

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Wed, 24 Apr 2024 08:00:00 -0400 - 1 year ago

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Thu, 18 Apr 2024 08:00:00 -0400 - 2 years ago

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Wed, 17 Apr 2024 08:00:00 -0400 - 2 years ago

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Tue, 05 Mar 2024 08:00:00 -0500 - 2 years ago

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Immutep Quarterly Activities Report Q2 FY24

Tue, 30 Jan 2024 08:00:00 -0500 - 2 years ago

Immutep Quarterly Activities Report Q2 FY24

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Thu, 04 Jan 2024 08:00:00 -0500 - 2 years ago

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Immutep: Upcoming Signals For 2024 (Maintain Buy)

Wed, 03 Jan 2024 17:04:38 -0500 - 2 years ago

Immutep: Upcoming Signals For 2024 (Maintain Buy)

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Thu, 21 Dec 2023 08:00:00 -0500 - 2 years ago

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Thu, 07 Dec 2023 08:00:00 -0500 - 2 years ago

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Wed, 22 Nov 2023 08:00:00 -0500 - 2 years ago

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Thu, 09 Nov 2023 08:00:00 -0500 - 2 years ago

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Mon, 06 Nov 2023 08:00:00 -0500 - 2 years ago

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep to Participate in November Investor Events

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Immutep to Participate in November Investor Events

Immutep Quarterly Activities Report Q1 FY24

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Immutep Quarterly Activities Report Q1 FY24

Immutep receives ~A$1.13 million R&D Tax Incentive

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Immutep receives ~A$1.13 million R&D Tax Incentive

NOCKNOCK
NOCKNOCK Feb. 24 at 3:34 PM
$IMMP
0 · Reply
TheIrishCzar
TheIrishCzar Feb. 24 at 1:55 PM
$IMMP options market is expecting a big move one way or the other by March expiration
0 · Reply
Pupssavethe
Pupssavethe Feb. 24 at 1:22 PM
$IMMP brewing big time and it is not my coffee
0 · Reply
TheIrishCzar
TheIrishCzar Feb. 24 at 12:05 AM
$IMMP citizen’s upped its price target to $10, just 6 days after setting a 6$ target. Hmmm? https://www.gurufocus.com/news/8642747/immutep-immp-receives-updated-analyst-coverage-with-new-price-target-immp-stock-news
0 · Reply
bylocehi
bylocehi Feb. 23 at 7:46 PM
$IMMP suspect buyers are short sellers closing positions on a down day.
0 · Reply
NOCKNOCK
NOCKNOCK Feb. 23 at 2:58 PM
$IMMP
0 · Reply
IFeelLike
IFeelLike Feb. 22 at 6:28 PM
$IMMP want to emphasize this again.... Concerning Tacti-004: NEW STANDARD OF CARE!! More numbers: market size expected to be 48 billion USD!!
3 · Reply
IFeelLike
IFeelLike Feb. 22 at 6:18 PM
$IMMP numbers don't lie.... Immutep the only one to address all Lung cancer populations as mentioned here👌💪
0 · Reply
allsign
allsign Feb. 21 at 8:38 AM
$IMMP https://www.immutep.com/dw/uploads/2026/02/Immutep_Corporate_Presentation_Feb2026.pdf
1 · Reply
NOCKNOCK
NOCKNOCK Feb. 21 at 12:14 AM
$IMMP
0 · Reply
higeki
higeki Feb. 20 at 2:03 AM
$IMMP wyckoff accumulation phase e , have had a position in this junk for too long but finally it looks ready to go and already up big. Much more to go maybe a 5x-10x bagger
0 · Reply
TradeOptionsDrinkScotch
TradeOptionsDrinkScotch Feb. 19 at 10:12 PM
$IMMP a Friday gap and go special would be nice🤞🏻
0 · Reply
bylocehi
bylocehi Feb. 19 at 8:44 PM
$IMMP A short seller saturation point occurs when a stock’s borrowable shares are fully utilized (100% utilization), making it nearly impossible to open new short positions. At this peak, high borrowing costs and limited inventory increase risk, often acting as a catalyst for a short squeeze when positive news forces buying. Think we are there.
1 · Reply
Tulipsdulips
Tulipsdulips Feb. 19 at 7:41 PM
$IMMP SOON.
1 · Reply
SouthernAccent
SouthernAccent Feb. 19 at 5:53 AM
$IMMP Positive futility news anyday now so strap in........
0 · Reply
ckruel
ckruel Feb. 18 at 5:29 PM
$IMMP
0 · Reply
MR79
MR79 Feb. 18 at 1:42 PM
$IMMP
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 11:52 AM
$IMMP RSI: 36.75, MACD: -0.0300 Vol: 0.17, MA20: 2.84, MA50: 2.78 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
MR79
MR79 Feb. 18 at 7:30 AM
$IMMP nice volume ASX
0 · Reply
IFeelLike
IFeelLike Feb. 17 at 9:57 PM
$IMMP so first in Q1 expected the futility analyses on Tacti-004 Then also in first half of 2026, update on IMP761 The LAG-3 (lymphocyte-activation gene-3) immune checkpoint has been identified as a promising therapeutic target for many autoimmune diseases, including rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis.1-3 IMP761 is the first LAG-3 agonist antibody developed to potentially treat these large, increasingly prevalent disorders, each of which represent multi-billion dollar markets. These 3 mentioned immune diseases are markets combined worth around 90 billion dollars in 5 of 6 years. https://www.immutep.com/immutep-announces-positive-update-on-imp761-a-first-in-class-lag-3-agonist-antibody-for-autoimmune-diseases-from-phase-i-study/ The Eftisarc neo trial, anybody knows when we can expect news on that?
0 · Reply
bylocehi
bylocehi Feb. 17 at 7:45 PM
$IMMP After years of delays we will be ready for take off after futility analysis Shareprice will sky rocket afterwards until 2027 FDA approval review
0 · Reply
Chavo184
Chavo184 Feb. 17 at 5:45 PM
$IMMP
0 · Reply